Treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus in a renal dysfunction patient undergoing adjustments to the linezolid dose.

Abstract

This study is the first case report of the treatment of methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis using therapeutic drug monitoring of the serum and wound exudate concentrations of linezolid in a renal dysfunction patient. In the present study, the serum trough concentration of linezolid was maintained between 2 and 7 μg/mL. Therapeutic drug monitoring dosage adjustments may be especially useful in patients with renal dysfunction and severe MRSA infection.

• Authors: Yasuhiro Tsuji, Masato Tashiro, Nobuyuki Ashizawa, Yukio Ota, Hayato Obi, Saori Nagura, Munetoshi Narukawa, Kazuaki Fukahara, Naoki Yoshimura, Hideto To, Yoshihiro Yamamoto
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 54 Issue 2 Pg. 235-9 ( 2015) ISSN: 1349-7235 [Electronic] Japan
• PMID: 25743019 (Publication Type: Case Reports, Journal Article)

Chemical References

• Acetamides
• Oxazolidinones
• Linezolid

Topics

• Acetamides (administration & dosage, adverse effects, therapeutic use)
• Aged
• Cardiac Surgical Procedures (adverse effects)
• Humans
• Linezolid
• Male
• Mediastinitis (drug therapy, epidemiology)
• Methicillin-Resistant Staphylococcus aureus
• Oxazolidinones (administration & dosage, adverse effects, therapeutic use)
• Postoperative Complications (microbiology)
• Renal Insufficiency (epidemiology)
• Staphylococcal Infections (drug therapy)
• Thrombocytopenia (chemically induced)